## 5 Conclusions
\begin{table}
\begin{tabular}{c c c c c c c c c c c c} \hline \hline \multirow{2}{*}{**Authors**} & **Risk** & \multirow{2}{*}{**Group**} & \multirow{2}{*}{\begin{tabular}{c} **Patient** \\ **Cohort** \\ \end{tabular} } & \multicolumn{2}{c}{\begin{tabular}{c} **Dose per Fraction** \\ **(Gy)** \\ \end{tabular} } & \multirow{2}{*}{\begin{tabular}{c} **Total** \\ **Fraction** \\ \end{tabular} } & \multirow{2}{*}{\begin{tabular}{c} **Follow-Up** \\ **(Months)** \\ \end{tabular} } & \multirow{2}{*}{**bRFS**} & \multicolumn{2}{c}{\
\begin{tabular}{c} **Acute G2+** \\ **Toxicity** \\ \end{tabular} } & \multicolumn{2}{c}{
\begin{tabular}{c} **Late G2+** \\ **Toxicity** \\ \end{tabular} } \\ \cline{5-12} \cline{8-11} \multicolumn{1}{c}{} & & **Prostate** & & **SIB** & & **GU** & **GI** & **GU** & **GI** \\ \hline [PERSON] et al. [19], & Int., & \multirow{2}{*}{8} & \multirow{2}{*}{7.25} & \multirow{2}{*}{9.5} & \multirow{2}{*}{5} & \multirow{2}{*}{56} & \multirow{2}{*}{100\%} & \multirow{2}{*}{37.5\%} & \multirow{2}{*}{37.5\%} & \multirow{2}{*}{12.5\%} & \multirow{2}{*}{0\%} \\
2020 & High & & & & & & & & & & \\ \[PERSON] et al. [24], & Low, Int. & \multirow{2}{*}{309} & \multirow{2}{*}{8} & \multirow{2}{*}{-} & \multirow{2}{*}{5} & \multirow{2}{*}{61} & \multirow{2}{*}{97.2\%} & \multirow{2}{*}{26\%} & \multirow{2}{*}{8.1\%} & \multirow{2}{*}{13.3\%} & \multirow{2}{*}{2\%} \\
2018 & & & & & & & & & & & \\ \[PERSON] et al. [25], & Low, Int., & \multirow{2}{*}{213} & \multirow{2}{*}{7.25} & \multirow{2}{*}{-} & \multirow{2}{*}{5} & \multirow{2}{*}{64} & \multirow{2}{*}{87.5\%} (L) & \multirow{2}{*}{NA} & \multirow{2}{*}{NA} & \multirow{2}{*}{NA} & \multirow{2}{*}{NA} \\
2020 & High & & & & & & & & & \\ \[PERSON] et al. [26], 2012 & Low & 304 & 7.25 & - & 5 & 32 & 94\% & NA & NA & 8.5\% & 2\% \\ \[PERSON] et al. [27], & Low & 41 & 7/7.25 & - & 5 & 60 & 93\% & 7\% & NA & 7\% & 2.5\% \\ \[PERSON] et al. [28], 2013 & Low, Int., & \multirow{2}{*}{304} & \multirow{2}{*}{7/7.25} & \multirow{2}{*}{-} & \multirow{2}{*}{5} & \multirow{2}{*}{60} & \multirow{2}{*}{90\% (L) 74\% (H)} & \multirow{2}{*}{4.6\%} & \multirow{2}{*}{3.6\%} & \multirow{2}{*}{9.9\%} & \multirow{2}{*}{4.5\%} \\  & High & & & & & & & & & \\ \[PERSON] et al. [29], & Low, Int. & \multirow{2}{*}{79} & \multirow{2}{*}{9.5} & \multirow{2}{*}{-} & \multirow{2}{*}{4} & \multirow{2}{*}{60} & \multirow{2}{*}{100\% (L) 92\% (D)} & \multirow{2}{*}{0\%} & \multirow{2}{*}{15\%} & \multirow{2}{*}{1\%} \\
2014 & & & & & & & & & \\ \[PERSON] et al. [37], & Low, Int. & \multirow{2}{*}{50} & \multirow{2}{*}{9.5} & \multirow{2}{*}{11} & \multirow{2}{*}{4} & \multirow{2}{*}{23} & \multirow{2}{*}{100\%} & \multirow{2}{*}{23\%} & \multirow{2}{*}{14\%} & \multirow{2}{*}{16\%} & \multirow{2}{*}{3\%} \\
2013 & & & & & & & & & & \\ \[PERSON] et al. [38], 2018 & Int., & \multirow{2}{*}{9} & \multirow{2}{*}{7.25} & \multirow{2}{*}{9-9.5-10} & \multirow{2}{*}{5} & \multirow{2}{*}{3} & \multirow{2}{*}{100\%} & \multirow{2}{*}{25\%} & \multirow{2}{*}{5\%} & \multirow{2}{*}{NA} & \multirow{2}{*}{NA} \\
2018 & High & & & & & & & & & \\ \hline [PERSON] et al. [39], 2021 & Low, & \multirow{2}{*}{133} & \multirow{2}{*}{7.5} & \multirow{2}{*}{-} & \multirow{2}{*}{5} & \multirow{2}{*}{60} & \multirow{2}{*}{83.6\%} & \multirow{2}{*}{1.5\%} & \multirow{2}{*}{0.8\%} & \multirow{2}{*}{2.3\%} & \multirow{2}{*}{0\%} \\ \hline \hline \end{tabular}
\end{table} 
Table 5: Overview of published literature of CyberKnife UH-SBRT with or without concomitant DIL boost. **Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of IEO, European Institute of Oncology, IRCCS (UID number IEO 1872, 15 November 2022). **Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study. **Data Availability Statement:** The data presented in this study are available upon reasonable request from the corresponding author.